Valuation: Clene Inc.

Market Cap 64.08M 55.71M 51.85M 47.61M 89.9M 6.12B 91.29M 611M 240M 3.05B 241M 235M 10.21B P/E 2026 *
-2.81x
P/E 2027 * -3.41x
Enterprise Value 50.68M 44.06M 41.01M 37.65M 71.1M 4.84B 72.2M 483M 190M 2.41B 190M 186M 8.08B EV / Sales 2026 *
244x
EV / Sales 2027 * 1.81x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day-0.50%
1 week-6.96%
1 month-18.52%
3 months-18.59%
6 months+22.62%
Current year-14.57%
1 week 4.63
Extreme 4.63
5.47
1 month 4.63
Extreme 4.63
6.55
Current year 3.88
Extreme 3.88
8.67
1 year 3.5
Extreme 3.5001
13.5
3 years 2.28
Extreme 2.2801
15.57
5 years 2.28
Extreme 2.2801
196.8
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 31/03/2013
Chief Tech/Sci/R&D Officer 67 31/12/2012
Director of Finance/CFO 57 31/01/2022
Director TitleAgeSince
Chairman 65 31/10/2015
Director/Board Member 53 31/08/2019
Director/Board Member 49 30/11/2020
Date Insider Type Main position Quantity % Market Cap.
04/05/26 Sell -72,884 0.6188%
19/02/26 Free

Founder

3,306 0.0281%
19/02/26 Free

Director

3,168 0.0269%
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%-6.96%+41.67%-67.69% 64.08M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.16%-4.11%+35.20%+134.85% 23.39B
Weighted average by Cap. +0.23%-2.96%+28.67%+119.93%

Financials

2026 *2027 *
Net sales 207K 180K 168K 154K 291K 19.8M 295K 1.98M 776K 9.86M 779K 762K 33.05M 23.64M 20.55M 19.13M 17.56M 33.17M 2.26B 33.68M 226M 88.5M 1.12B 88.8M 86.85M 3.77B
Net income -25.09M -21.81M -20.3M -18.64M -35.2M -2.4B -35.75M -239M -93.93M -1.19B -94.24M -92.17M -4B -27.55M -23.95M -22.29M -20.46M -38.65M -2.63B -39.24M -263M -103M -1.31B -103M -101M -4.39B
Net Debt -13.4M -11.65M -10.84M -9.95M -18.8M -1.28B -19.09M -128M -50.16M -637M -50.33M -49.22M -2.14B -21.4M -18.6M -17.32M -15.9M -30.02M -2.04B -30.49M -204M -80.1M -1.02B -80.37M -78.6M -3.41B
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
78
Date Price Change Volume
31/07/26 US$5.015 -0.50% 33,748
30/07/26 US$5.040 +6.78% 37,350
29/07/26 US$4.720 -5.41% 140,746
28/07/26 US$4.990 -8.61% 93,043
27/07/26 US$5.460 +1.30% 28,258
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.015USD
Average target price
32.20USD
Spread / Average Target
+542.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock